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Background: Subacromial impingement is a common cause of shoulder complaints in general practice. When the
initial treatment with acetaminophen and low dose Non Steroidal Anti Inflammatory Drugs fails, triamcinolone
acetonide injections are commonly used. Triamcinolone acetonide injections are effective at four to six weeks. Little
is known about the pain relief effect of triamcinolone acetonide injections in the first days after injection and the
effect of repeated injection. In this study we investigate the effect of triamcinolone acetonide injections compared
to hyaluronic acid and NaCl injections using a pain diary.
Methods: 159 Patients recruited for an RCT comparing the effect of subacromial injections of triamcinolone
acetonide, hyaluronic acid and sodium chloride (NaCl) were used in this study. They were blinded for their
treatment and could receive up to three injections. Primary outcome consisted of the patient perceived pain on a
VAS score recorded on a daily basis during 21 days following injection. Secondary outcome consisted of the
amount of taken escape medication following injection and adverse effects.
Results: All patients received the first injection. 150 patients also received the second and third injections. 97% Of
the paper and pencil pain diaries were returned for data analysis.
The triamcinolone acetonide group showed the largest decrease in pain on the VAS scores after injection
compared to the hyaluronic acid and NaCl group in the first week after injection. The reduction in pain was best
achieved after the first injection, the second triamcinolone acetonide injection showed a further reduction in pain.
The third triamcinolone acetonide injection only showed a slight improvement in pain reduction.
Conclusions: In this study we could show a booster effect in pain reduction after repeated triamcinolone
acetonide injection. The triamcinolone acetonide group showed a faster reduction in pain after injection compared
to the hyaluronic acid and NaCl group. The effect was best seen after the first and second triamcinolone acetonide
injection, it is therefore questionable whether it is necessary to repeat triamcinolone acetonide injections more than
two times.
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Shoulder complaints are frequently encountered in
General Practice [1,2], of which subacromial impinge-
ment is a common cause [3]. Early symptoms of suba-
cromial impingement are treated with acetaminophen
(paracetamol) or low-doses of non-steroidal anti-
inflammatory drugs. When this therapy fails, impinge-
ment can be treated with subacromial injections. These
injections merely consist of a combination of a corti-
costeroid and a local anesthetic [4,5]. Although it is
known that corticosteroids are effective at short term,
four to six weeks, only a few studies have investigated
the effect of corticosteroids in the first days after injec-
tion. In the study of Lewis this was investigated for the
treatment in lateral epicondylitis of the elbow in the
review of Coombs this consisted of the study of the ef-
fectiveness of injections in a number of different tendi-
nopathy pathologies like lateral epicondylalgia, medial
epicondylalgia, rotator-cuff tendinopathy, Achilles ten-
dinopathy and patellar tendinopathy [6,7]. These drug
treatments are commonly combined with exercises and
physiotherapy, the combination of subacromial injec-
tions and physiotherapy are stated to give a better re-
sult [8].
A few studies have shown improvement in pain and
function following the subacromial injection of hyaluronic
acid alone [9-12].
Hyaluronic acid is thought to serve as a lubricant [13]
and is reported to have an anti-inflammatory effect [14].
Several studies have investigated the side effect of cor-
ticosteroid injections, in these studies only few side ef-
fects are described provided injections are not repeated
too often at the same site [15]. Some animal studies re-
ported negative side effects concerning weakening of the
rat rotator cuff in the first weeks after administration
[16-18]. The corticosteroid injection reduces the inflam-
mation and pain associated with the subacromial im-
pingement [19].
Little is known about the effect on pain reduction after
repeated corticosteroid injection [20,21].
This study was part of a randomized clinical trial RCT,
with a three arm design in which hyaluronic acid + lidocaine
1% (A) were compared to triamcinolone acetonide + lidocaine
1% (B) and placebo sodium chloride (NaCl) + lidocaine 1%
(C). In this trial we could prove a significant improvement
in pain for triamcinolone acetonide after three, six and
twelve weeks. Compared to placebo, injections containing
hyaluronic acid did not show a significant improvement in
pain [22].
In this study we investigated the effect of subacromial
injections in the first days after administration. We also
investigated the effect of repetition of subacromial injec-
tions on the perceived amount of pain in order to study
an accumulative effect of repeated injection.Methods
Setting and participants
This study was approved by the Medical Ethics Review
Committee (MERC) of the Maastricht University Medical
Center (MUMC) and was performed at the outpatient
clinic of our orthopedic surgery department. Written in-
formed consent was obtained from participants. A total of
159 patients were included in the study, including 75 men
and 84 women with a mean age of 53 years (range 20 to
87). A large majority of patients could be included after
direct referral by general practitioners. These patients did
not receive prior injection treatment by their general prac-
titioners for their current episode of shoulder pain.
Patients were randomized into three treatment groups
and were blinded for their respective treatment. Eligible
patients were over 18 years of age and had pain in the
shoulder, either at rest or on movement. The diagnosis
of impingement was made clinically without the routine
use of ultrasound or MRI. All presented with a painful
arc, with or without abnormal scapulohumeral movement.
Exclusion criteria included: pain for less than six weeks;
injection with corticosteroids in the preceding three
months; flexion of <100° in the frontal plane; external ro-
tation limited by >50% compared with the opposite side;
allergy to lidocaine 1%, steroids or hyaluronic acid; preg-
nancy or suspected pregnancy; dementia; prior infection
of the shoulder joints; tumour; osteoporosis; rheumatoid
arthritis according to the American College of Rheumatol-
ogy (ACR) criteria [23]; referred pain, such as from the
neck; an associated neurological disorder; polymyalgia; an-
kylosing spondylitis as diagnosed using the modified New
York (NY) criteria [24]; whiplash injury; previous fractures
or surgery on the shoulder, upper limb, neck or thorax;
and behavioural, cognitive or psychiatric disorders. Pa-
tients unable to complete Dutch questionnaires independ-
ently or reluctant to adhere to the allocated treatment or
to complete follow-up were also excluded [22].
Intervention
Treatment consisted of subacromial injection with either:
a mixture of 8 ml lidocaine 1% and 2 ml hyaluronic acid
(Ostenil) (TRB CHEMEDICA, Haar/München, Germany)
(group A); a mixture of 8 ml lidocaine 1% with 2 ml triam-
cinolone acetonide 10 mg/ml (group B); or a mixture of
8 ml lidocaine 1% with 2 ml NaCl 0.9% (placebo; group C).
Injections were repeated, if necessary, after three and six
weeks. In case of complete resolution of pain, no further
injections were given [22].
Randomization
Patients were randomized blindly into three treatment
groups. An independent statistician (FK) generated a
random numbers list which, by permutation of random
blocks, block size 9, was balanced for treatments within
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After selection and baseline assessment, consecutive num-
bered opaque envelopes of the appropriate stratum were
opened by one of several independent trial nurses.
A total of 51 patients were randomized into group A,
53 into group B and 55 into group C [22].
Blinding
All injections were administered by the same physician
(LIFP). Both physician and patients were blinded to the
contents of the syringe. In order to achieve an effective
blinded injection a 19 gauge 1.5 inch needle and a 10 ml
syringe were used to prevent the physician identifying
the difference in viscosity of the administered solutions.
The syringes were filled by an independent trial nurse
and masked with black adhesive tape. The nurse was
thus responsible for the blinding procedure. Inclusion,
follow-up assessments and data analysis were blinded for
allocated treatment [22].
Administration of injection
Injections were administered via a dorsolateral approach
through the interval just beneath the dorsal acromial
edge, with the patient sitting up [25]. The injection site
was marked and disinfected with iodine, or with chlor-
hexidine solution in case of known allergy.
Outcome assessment
The primary outcome measure was pain as measured on
a horizontal 10 cm visual analogue scale (VAS) (0, no
pain to 10, severe pain) [26]. Measurements were taken
at consultation before injection. The first 21 days after
each injection patients were asked to record a VAS score
each day in their pain diary.
We investigated the effect of injections of A, B and C
on a daily basis using a pain diary during the 21th days
after injection. In this study we focus on the effects of
repeated triamcinolone acetonide injections versus pla-
cebo and hyaluronic acid, illustrating the potential benefit
of a series of injections.
The pain diary was used to record the perceived amount
of pain. With the pain diary we are able to show the im-
mediate daily response the first days after injection. Pain
diaries have been shown to be valid and reliable in the
measurement of pain in patients with chronic pain and
cancer. It is reported that patients tend to overestimate
their remembered pain and psychosocial and pain re-
lated factors tend to bias the remembered pain. The
daily self-recording of pain by a pain diary showed to re-
duce the amount of bias [27].
Secondary outcome measures consisted of the type and
amount of escape medication taken and the occurrence of
adverse effects.During the first visit patients were thoroughly instructed
how to fill out the paper and pencil pain diary. Patients
were told to record the maximum experienced pain for
each day.
In the pain dairies the days were separated. For each day
a VAS score could be recorded on a 10 cm line.
Although patients were instructed that only escape
medication consisting of acetaminophen (paracetamol)
was allowed, they were asked to record the type and
amount of escape medication taken for each day.
A final question for each day consisted of the occur-
rence of adverse effects. The perceived adverse events
were recorded on a text free basis.
Patients were instructed to complete the diary on a daily
basis, they were suggested to fill out the diary at the same
moment each day to improve compliance.
Statistical analysis
For this study we obtained data of patients enrolled in
the RCT. The number of participants was based on the
power calculation used for the RCT in which we had
calculated a total number of 159 participants, 53, per
group, allowing for a dropout rate of 10%. The power
calculation of the RCT was based on the decrease in
pain on a VAS score [22].
First, data were tested for normality. Second, a missing
value analysis was performed. In case of loss to follow-
up or withdrawal resulting in missing data, these values
were handled by the method of linear trend at point im-
putation. Analysis of variance was used to establish ef-
fects of both interventions. The influence of prognostic
variables and baseline differences for outcome measures
was assessed in a multivariate linear regression model
with imputation of most important baseline variables.
Influential variables were used to correct the outcome of
the analysis of variance. Statistical significance was set at
a p-value <0.05 [22].
Results
All of the 159 included patients received the first allo-
cated injection. The second and third allocated injec-
tions were received by 150 patients. Nine patients (6%)
did not receive the second and third injection, 3 in each
of the groups. In the hyaluronic acid group reasons for
not receiving the allocated injections were: withdrawn
because of malignancy (n = 1), lost to follow up (n = 1)
and not wishing to continue (n = 1). In the triamcinolone
acetonide group reasons for not receiving the allocated
treatment were: withdrawn because of too much pain
(n = 1), lost to follow up (n = 1) and complete relieve of
pain after 2 injections (n = 1). In the NaCl injection
group reasons for not receiving the allocated treatment
consisted of too much pain (n = 2) and lost to follow
up (n = 1). [22] Figure 1.
Randomisation
(159)
Allocated to treatment with Hyaluronic
Acid injections
(51)
Allocated to treatment with
corticosteroid injections
(53)
Allocated to treatment with
NaCl injections
(55)












Did not receive allocated treatment (3):
withdrawn malignancy (1)
withdrawn too much pain (1)
lost to follow up (1)
Did not receive allocated treatment (3):
withdrawn too much pain (1)
lost to follow up (1)
no pain (1)
Did not receive allocated treatment (3):
change to standard treatment (2)
lost to follow up (1)
Figure 1 Allocated treatment.
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corded [28]. In the hyaluronic acid group we report a
positive Neer test in 61%, in the triamcinolone group in
70,5% and in the NaCl group in 73%.
The analysis at baseline did not show any significant
differences among the groups. At baseline the VAS score
of the triamcinolone acetonide group was 5.8 (95% CI
5.1-6.5), of the hyaluronic acid group 6.1(95% CI 5.4-6.8)
and of the NaCl group was 5.9 (95% CI 5.1-6.5).
3% (n = 14) of the diaries was not returned, due to
withdrawal from the study or lost diaries. In the hyalur-
onic acid group four diaries from the, first period, and
two diaries of the second and third period were not
returned. In the triamcinolone acetonide group two diar-
ies in the first period, and one diary in the second and
third period were not returned. For the NaCl group in
both the first and second period one diary was not
returned. In the third period al diaries were returned.
(Table 1) Mean VAS scores and according trend lines
are depicted in Figures 2, 3 and 4 and in Tables 2, 3 and
4. After the first injection a remarkable drop in VAS
score is shown for the first week in the triamcinolone




acetonide (n = 53)
NaCl (n = 55)
Week 0 - 3 4 2 1
Week 3 - 6 2 1 1
Week 6 - 9 2 1 0in pain although the VAS score stays below the level of
pain before injection at three weeks. The hyaluronic acid
and NaCl group show only slight improvement in pain
reduction with a less steep curve. After the second injec-
tion a slight improvement in pain is seen for the hyalur-
onic acid group and the NaCl group although the effect
is limited compared to the effect after the first injection.
After the third injection little change is shown in the
VAS scores for all groups.
Concerning the secondary outcome measures we re-
port significant differences in the number of persons in
need of escape medication. The hyaluronic acid group
and the NaCl group needed significantly more escape
medication because of pain throughout the study Tables 5,
6 and 7.
Adverse effects described in the free text of the pain
diaries consisted of: flushes, headache, nausea, redness
at injection site and tingling sensations. 24 patients re-
ported adverse effect, The most reported adverse effect
was occurrence of headache. This occurred in 8 patients
in the hyaluronic acid group, in 5 patients in the triam-
cinolone acetonide group and in 4 patients in the NaCl
group Table 8.
Discussion
We could show a significant reduction in pain after a tri-
amcinolone acetonide injection as we described in the
results of the RCT [22]. In the data of the pain diaries
we found a faster reduction and steeper downward curve
in the triamcinolone acetonide group compared to the
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Figure 2 Daily VAS scores after first injection and according linear trend lines. Legend: (green triangle) hyaluronic acid. (red square) NaCl.
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Figure 3 Daily VAS scores after second injection and according linear trend lines. Legend: (green triangle) hyaluronic acid. (red square)
NaCl. (blue diamond) triamcinolone acetonide.
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Figure 4 Daily VAS scores after third injection and according linear trend lines. Legend: (green triangle) hyaluronic acid. (red square) NaCl.
(blue diamond) triamcinolone acetonide.
Table 2 Mean visual analogue scale (0–10) after the first
injection
Day Hyaluronic acid Triamcinolone acetonide NaCl Sig.
0 6,1 5,8 5,9 ,845
1 6,1 4,8 5,4 ,052
2 5,8 4,3 5,5 ,021
3 5,6 4,2 5,5 ,014
4 5,5 4,2 5,7 ,008
5 5,6 3,8 5,2 ,002
6 5,2 3,6 5,0 ,002
7 5,5 3,5 5,5 ,000
8 5,5 3,4 5,2 ,000
9 5,6 3,7 5,0 ,001
10 5,6 3,9 5,0 ,005
11 5,8 4,2 5,1 ,009
12 5,7 3,9 5,2 ,002
13 6,1 4,0 5,1 ,000
14 6,0 4,0 5,0 ,000
15 5,7 3,8 4,9 ,001
16 5,7 4,1 4,8 ,008
17 5,7 4,0 5,1 ,004
18 5,6 4,4 5,3 ,046
19 5,3 4,2 4,9 ,059
20 5,4 4,1 4,7 ,018
21 5,4 4,2 4,8 ,013
Table 3 Mean visual analogue scale (0–10) after the
second injection
Day Hyaluronic acid Triamcinolone acetonide NaCl Sig.
0 5,9 4,4 5,2 ,017
1 5,2 3,8 4,7 ,022
2 5,3 3,6 5,1 ,004
3 5,1 3,4 4,7 ,005
4 5,3 3,6 4,8 ,005
5 5,1 3,4 4,4 ,004
6 5,2 3,4 4,6 ,003
7 5,3 3,2 4,6 ,000
8 5,2 3,1 4,5 ,000
9 5,3 3,3 4,5 ,001
10 5,2 3,4 4,6 ,003
11 5,2 3,5 4,6 ,006
12 5,2 3,5 4,7 ,008
13 5,0 3,1 4,3 ,003
14 4,9 3,1 4,5 ,003
15 5,0 3,0 4,5 ,001
16 5,0 3,2 4,4 ,003
17 4,9 3,2 4,3 ,005
18 4,8 3,3 4,2 ,023
19 4,6 3,5 4,0 ,088
20 4,6 3,5 4,2 ,093
21 4,6 3,2 4,1 ,006
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Table 4 Mean visual analogue scale (0–10) after the third
injection
Day Hyaluronic acid Triamcinolone acetonide NaCl Sig.
0 5,4 3,1 4,5 ,000
1 5,1 2,6 4,3 ,000
2 5,3 2,6 4,0 ,000
3 5,2 2,6 4,1 ,000
4 5,1 2,8 4,3 ,000
5 4,8 2,5 3,9 ,000
6 4,8 2,5 3,9 ,000
7 4,9 2,4 3,7 ,000
8 5,0 2,5 4,0 ,000
9 5,1 2,5 3,8 ,000
10 5,1 2,6 3,9 ,000
11 5,0 2,9 4,0 ,001
12 4,9 3,0 3,7 ,001
13 4,8 2,8 3,7 ,001
14 4,8 2,7 3,8 ,001
15 4,9 2,8 3,5 ,000
16 5,1 2,8 3,6 ,000
17 5,0 3,0 3,9 ,001
18 4,9 2,8 4,0 ,001
19 5,1 2,7 3,8 ,000
20 4,8 2,8 3,7 ,000
21 4,7 2,7 3,6 ,000
Table 5 Number of persons (n) in need of escape
medication after the first injection
Day Hyaluronic acid Triamcinolone acetonide NaCl Sign.
1 20 10 20 ,051
2 21 11 19 ,051
3 17 13 15 ,514
4 15 13 17 ,665
5 22 14 18 ,142
6 19 14 19 ,379
7 18 10 20 ,061
8 21 10 20 ,022
9 23 7 20 ,001
10 20 8 21 ,005
11 21 9 25 ,002
12 20 7 19 ,003
13 23 8 20 ,001
14 18 7 20 ,006
15 24 6 19 ,000
16 21 11 15 ,029
17 21 9 17 ,007
18 18 10 17 ,063
19 15 6 13 ,011
20 15 8 14 ,049
21 8 6 8 ,510
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tion of pain in the triamcinolone acetonide group, this
effect was not seen in the hyaluronic acid and NaCl
group. Little is known about the pattern of perceived
pain after corticosteroid injection, by means of the re-
corded VAS scores we were able to give a graphic better
description of this pattern. In the study of Lewis et al.
the pain after corticosteroid injection in Tennis Elbow
complaints was described as an increase in pain for the
first day after injection and a reduction after three to
four days. In our study we have not found an increase in
pain as reported on the VAS score after the subacromial
injections [7].
In literature most studies describe a repetition of cor-
ticosteroid injections in the treatment of shoulder disor-
ders [19,21].
A number of studies focus on the negative side effects
of corticosteroid injections. In these studies merely the
effect on the cuff tissue is described with increased
damage of this tissue as summarized in the systematic
review of Dean [18]. The group of Bathia however
could not show a significant higher number of cuff rup-
tures after higher numbers of repeated corticosteroidinjections [20]. The group of Mykolyzk showed a re-
versible effect of these tissues after 3 weeks [17]. Based
on these findings there seems to be some evidence to be-
lief that cuff tissue has the ability to recover after cortico-
steroid injection and that repetition of corticosteroid
injections does not necessary lead to increased numbers
of cuff ruptures.
There are some limitations concerning our study, the
selection of patients before entering the study was per-
formed without use of MRI or Ultrasound, this might
give some bias in the selection. In general practice how-
ever most patients will be treated based on a clinical
diagnosis. The results of this study therefore can be used
for extrapolation to general practice.
The injections where placed without use of ultrasound
guidance. A recent study however showed that there is
little evidence for the need of ultrasound guided needle
placement [29].
As far as we know there are no studies which show
the short term accumulative effect of corticosteroids
in pain reduction. One of the strengths of our study
is that we were able to show a booster effect of a repeated
triamcinolone acetonide injection after the second
injection.
Table 6 Number of persons (n) in need of escape
medication after the second injection
Day Hyaluronic acid Triamcinolone acetonide NaCl Sign.
1 13 18 14 ,292
2 19 6 17 ,003
3 14 5 14 ,031
4 18 7 17 ,014
5 20 6 17 ,002
6 21 6 16 ,001
7 20 7 17 ,005
8 22 8 13 ,001
9 21 8 14 ,005
10 23 6 16 ,000
11 19 9 14 ,037
12 18 8 17 ,036
13 19 8 15 ,022
14 22 8 15 ,003
15 21 11 17 ,047
16 18 8 16 ,038
17 18 6 18 ,003
18 17 6 15 ,010
19 16 6 14 ,011
20 12 5 14 ,061
21 12 5 13 ,068
Table 7 Number of persons (n) in need of escape
medication after the third injection
Day Hyaluronic acid Triamcinolone acetonide NaCl Sign.
1 20 5 12 ,001
2 22 6 9 ,000
3 22 5 11 ,000
4 18 5 10 ,003
5 19 3 10 ,000
6 20 3 10 ,000
7 20 4 11 ,000
8 16 5 11 ,014
9 20 4 11 ,000
10 19 4 11 ,001
11 20 5 12 ,001
12 19 5 11 ,002
13 21 4 10 ,000
14 20 7 11 ,004
15 23 4 10 ,000
16 24 3 10 ,000
17 22 4 12 ,000
18 19 3 12 ,000
19 21 4 10 ,000
20 18 5 10 ,002
21 21 3 9 ,000












Headache 8 5 4
Tingling 1
Nausea 2 2
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show a significant reduction in pain on a VAS score after
triamcinolone acetonide injection at three, six and twelve
weeks. In the current study we were able to show the re-
sults at nine weeks after the start of the trial. Given the
limited effect of reduction in pain after the third injection
it is questionable whether it is necessary to administer
more than two injections in case of subacromial impinge-
ment [22].
An increase in pain after corticosteroid injection is a
common adverse effect [19]. Although compared to
other studies in which the effect of corticosteroids was
studied in the treatment of lateral epicondylitis, in our
study the amount of perceived pain after triamcino-
lone acetonide injection was limited [7]. Patients in
the hyaluronic acid group needed significantly more
co-medication compared to patients in the triamcino-
lone acetonide group.
Conclusions
In the first week after injection of triamcinolone aceto-
nide we could show a fast reduction in pain. After the
second injection we could show a limited booster effect
of repeated triamcinolone acetonide injection. We wereable to graphically show this booster effect of fast reduc-
tion in pain after the triamcinolone acetonide injection
by displaying the patient perceived pain on a VAS score
in the days after injection. Given the limited effect in
pain reduction after the third triamcinolone acetonide
injection there might be evidence to reduce the total
number of repeated triamcinolone acetonide injections
to two injections.
Compared to Hyaluronic acid and NaCl injections, tri-
amcinolone acetonide injections showed a fast and ef-
fective reduction in pain on a VAS score already after a
limited number of injections.
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